Tag: protein

GREELEY, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC), one of the world's leading food companies, reports its second quarter 2025 financial results.

Press Release - Regulated Information

New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company received the first notice from the Nasdaq Listings Qualifications office of the Nasdaq Stock Market LLC on July 23, 2025, informing the Company that as reflected in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on July 21, 2025, the Company failed to comply with the $2.5 million stockholder’s equity required under Nasdaq Rule 5550(b)(1) (the “Equity Rule”) or any alternative standard under Nasdaq 5550(b).